On the heels of pulmonary arterial hypertension drug nod, Merck launches 'Outnumber PAH' campaign
Mere weeks after earning the FDA’s signoff on new drug Winrevair to treat pulmonary arterial hypertension (PAH), Merck has kicked off an educational campaign around the rare disease. The “Outnumber PAH” initiative is aimed primarily at people diagnosed …